Botulism Pipeline Report provides an analysis of 4+ key companies and 5+ key pipeline therapies

DelveInsight's, "Botulism Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Botulism pipeline landscape.

Botulism Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Botulism pipeline landscape is provided which includes the disease overview and Botulism treatment guidelines. The assessment part of the report embraces, in depth Botulism commercial assessment and clinical assessment of the pipeline products under development.

In the Botulism Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Botulism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Botulism Pipeline Report
• DelveInsight's Botulism Pipeline report depicts a robust space with 04+ active players working to develop 05+ pipeline therapies for various indications.
• Leading Botulism Companies such as XOMA, CytoDel, AlphaVax, PanThera Biopharma, and others are developing potential drug candidates to improve the Botulism treatment scenario.
• The promising Botulism therapies such as Biodefence vaccines, NTM-1633, and others
• AlphaVax is developing immunostimulants as biodefence vaccines using Alphavaccine Platform System. The system is genetically derived from a modified alphavirus. The re-engineered alphavaccine particles express the substituted gene (or genes), rather than producing more virus particles, thereby transforming the original virus into a highly effective vaccine system. Alphavaccines is currently in preclinical development for the treatment of botulism.
• NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). The therapy is currently under Phase-I clinical development for the treatment of botulism.

Request a sample and discover the recent advances in Botulism @ https://www.delveinsight.com/sample-request/botulism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Botulism Overview

Botulism is a rare, naturally occurring disease that is caused by botulinum toxins from bacteria called Clostridium botulinum. It is transmitted through food, contact with contaminated soil, or through an open wound. The symptoms of Botulism include constipation, drooping eyelids, paralysis, difficulty swallowing or speaking, facial weakness on both sides of the face, blurred vision, trouble breathing, nausea, vomiting, and abdominal cramps (only in foodborne botulism).

A diagnosis of Botulism is made based upon a thorough physical examination, a detailed patient history, and a variety of specialized tests. The standard test is a brain scan, cerebrospinal fluid examination, electromyography, and/or edrophonium chloride test for myasthenia gravis. Early diagnosis with foodborne or wound botulism can be cured with antitoxin. The antitoxin attaches itself to toxin that's still circulating in bloodstream. In infants, a treatment known as botulism immune globulin blocks the actions of neurotoxins circulating in the blood. If the infection results from a wound, the wound needs to be treated surgically.

Botulism treatment consists of antitoxin administration, hospital admission, close monitoring, respiratory support as required, and debridement plus antibiotics in the case of wound botulism. Any patient with a clinical presentation concerning for botulism should be hospitalized immediately for close observation. Antitoxin therapy available to healthcare providers currently exists in two forms: heptavalent equine serum antitoxin, indicated for patients older than 1 year, and human-derived immunoglobulin, indicated for infants under the age of 1. Heptavalent equine serum antitoxin contains antibodies to BoNT/A-BoNT/G and is available through State Health Departments and the CDC.

Botulism Emerging Drugs
• Biodefence vaccines: AlphaVax
• NTM-1633: XOMA

Botulism Pipeline Therapeutics Analysis
There are approx. 4+ key companies which are developing therapies for Botulism. The companies which have their Botulism drug candidates in the most advanced stage, i.e. Phase I include, XOMA.

Know more about Botulism Therapeutics and Drug Pipeline Analysis @ https://www.delveinsight.com/sample-request/botulism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Botulism Pipeline Analysis Report
• The report provides detailed insights about emerging therapies for the Botulism treatment and the aggregate therapies developed by major pharma companies.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Botulism Treatment.
• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• The Botulism Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Botulism market.

The Botulism Pipeline Report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.

Scope of the Botulism Pipeline Report
Coverage- Global
Botulism Companies such as XOMA, CytoDel, AlphaVax, PanThera Biopharma, and others
Botulism therapies such as Biodefence vaccines, NTM-1633, and others
Botulism Pipeline-
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Botulism Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Botulism Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Botulism- Market Drivers and Barriers
Botulism- Future Perspectives and Conclusion
Botulism Analyst Views

Table of Content
1. Introduction
2. Executive Summary
3. Botulism: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Botulism - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Mid Stage Products (Phase II)
10. Drug name: Company name
11. Early Stage Products (Phase I)
12. NTM-1633: XOMA
13. Preclinical/Discovery Stage Products
14. Biodefence vaccines: AlphaVax
15. Inactive Products
16. Botulism Key Companies
17. Botulism Key Products
18. Botulism- Unmet Needs
19. Botulism- Market Drivers and Barriers
20. Botulism- Future Perspectives and Conclusion
21. Botulism Analyst Views
22. Appendix

For further information on the Botulism Pipeline Therapeutics, reach out @ https://www.delveinsight.com/report-store/botulism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.